Amendment: SEC Form SC 13D/A filed by Akili Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

Akili, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

 (Title of Class of Securities)

00974B107

(CUSIP Number)

Chamath Palihapitiya

c/o SC Master Holdings, LLC

506 Santa Cruz Avenue, Suite 300

Menlo Park, California 94025

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 2, 2024

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 00974B107

Item 1. Security and Issuer.

This Amendment No. 3 (this “Amendment”) to Schedule 13D amends and supplements the Schedule 13D filed with the United States Securities and Exchange Commission (“SEC”) on August 23, 2022, as amended to date (the “Schedule 13D”), relating to the common stock, par value $0.0001 per share (“Issuer Common Stock”), of Akili Inc., a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 125 Broad Street, Fifth Floor, Boston, Massachusetts 02110.

The items below amends and supplements the information disclosed under the corresponding item of the Schedule 13D. Capitalized terms defined in the Schedule 13D are used herein as so defined.

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

On May 29, 2024, SC Master Holdings, SC PIPE Holdings, Virtual Therapeutics Corporation and Alpha Merger Sub, Inc. (“Purchaser”), entered into a Tender and Support Agreement (the “Tender and Support Agreement”). The Tender and Support Agreement provides, among other things, that SC Master Holdings and SC PIPE Holdings will tender all of the shares of the Issuer Common Stock held by such stockholder to Purchaser in a cash tender offer and (if applicable) vote all of their shares of Issuer Common Stock in favor of a merger of Purchaser with and into the Issuer. The purchase price per share of the Issuer Common Stock in the tender offer will be $0.4340. The foregoing description of the Tender and Support Agreement does not purport to be complete and is qualified in its entirety by reference to the form of the Tender and Support Agreement, which is filed as Exhibit 8 to this Amendment and is incorporated by reference herein.

On July 2, 2024, the tender offer and merger described above closed.  The Reporting Persons sold an aggregate of 13,773,000 shares of Issuer Common Stock in the tender offer consisting of: (i) 8,100,000 shares of Issuer Common Stock held of record by SC PIPE Holdings LLC, (ii) 3,773,000 shares of Issuer Common Stock held of record by SC Master Holdings, LLC, and (iii) 1,900,000 shares of Issuer Common Stock held of record by a trust for the benefit of members of Mr. Palihapitiya’s immediate family.

Item 5. Interest in Securities of the Issuer.

Items 5(a)-(b) of the Schedule 13D are hereby amended and supplemented by the following:

The information contained on the cover pages of this Amendment is incorporated herein by reference.

Item 5(c) of the Schedule 13D is hereby amended and supplemented by the following:

The information contained in Item 4 of this Amendment is incorporated herein by reference.

Item 5(e) of the Schedule 13D is hereby amended and supplemented by the following:

As of July 2, 2024, the Reporting Persons ceased to beneficially own more than five percent of the outstanding Issuer Common Stock.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 5, 2024